Potential Increase in Fracture Risk with GLP-1 Drugs: Bone Issues Overlooked Amidst the "Weight Loss Drug" Hype

The discussion surrounding GLP-1 receptor agonists has rapidly expanded over the past few years. Beyond their role as diabetes treatments, their significant weight loss effects have made them widely known outside the medical field. Names like Ozempic, Wegovy, and Mounjaro have permeated even to those who don't usually follow medical news. The benefits, such as reduced cardiovascular risk and improved blood sugar management, are indeed substantial. Therefore, the newly emerging issue of "impact on bones" carries weight that cannot be dismissed as merely a side effect.

Fox News highlighted a study indicating that elderly type 2 diabetes patients had an 11% higher risk of fragility fractures after starting GLP-1 medications. This study, published in February 2026 in the 'Journal of Clinical Endocrinology & Metabolism,' followed 46,177 type 2 diabetes patients aged 65 and older, comparing those who began using GLP-1 receptor agonists with those using SGLT2 inhibitors or DPP-4 inhibitors. Over a median follow-up of 34.7 months, adjusted analyses showed an 11% higher risk of fragility fractures in the GLP-1 medication group.

What is crucial here is how to interpret the "11% higher" figure. While it might seem like a significant difference at first glance, this is an increase in relative risk, and it doesn't immediately translate to "dangerous for everyone" or "should be stopped immediately." The study authors themselves explain that the issue arises in a group already at high risk for fractures, being both "elderly" and "type 2 diabetes" patients. Thus, the study does not outright reject GLP-1 medications, but rather highlights the reality that because these drugs offer significant benefits, bone monitoring should not be neglected.

Moreover, concerns are not limited to fractures. Another study presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting showed that adults with type 2 diabetes and obesity who used GLP-1 medications had higher incidence rates over five years: **osteoporosis 4.1% vs. 3.2%, gout 7.4% vs. 6.6%, osteomalacia 0.2% vs. 0.1%** compared to non-users. Particularly, the risk of osteoporosis was about 29% higher, and the difference in osteomalacia was relatively larger. However, this is at the conference presentation stage and is a pre-peer-reviewed study. While the impact of the numbers should not be overstated, it serves as a significant warning that "the long-term effects on bones and joints need more attention."

So, why do these results occur? As of now, there is no single answer. Researchers and experts have proposed several plausible hypotheses. One is the reduction in bone load due to rapid weight loss. While losing weight is a health benefit for many, for bones, it means a reduction in "daily load stimulation." Bones weaken if not used. In extreme cases, the reduction in load can affect bone metabolism, similar to the phenomenon of bone loss in space.

Another hypothesis is nutritional deficiency. Since GLP-1 medications suppress appetite, the amount of food intake tends to decrease. While reducing overeating is a significant advantage, if essential nutrients for maintaining bones and muscles, such as protein, calcium, and vitamin D, are also lacking, it could be detrimental in the long run. Additionally, some people may have a biased diet due to nausea or gastrointestinal symptoms. If weight loss progresses without maintaining muscle and bone, the numbers on the scale might improve, but the "contents of the body" could weaken.

Another aspect not to be overlooked is muscle mass reduction. For the elderly, fractures are not only a bone issue but also a fall issue. If leg strength or core stability declines, the risk of falling increases, and combined with bone fragility, it can lead to fractures. Weight loss from GLP-1 medications can involve a reduction in lean body mass as well as fat, making it crucial to maintain muscle strength alongside dietary management. The issue is not the medication itself but rather receiving the medication's effects without a "muscle-preserving plan."

In fact, the research trend is not one-sided. A secondary analysis of a randomized controlled trial in 2024 showed that while one type of GLP-1 receptor agonist, liraglutide, alone was associated with decreased bone density in the hip and spine, the group that combined it with exercise maintained bone density. Moreover, the weight loss effect was greatest in the combined group. This is highly suggestive. The challenge with GLP-1 medications may not be simply "to use or not to use," but rather how to use them. The results can vary depending on whether exercise, especially resistance training or weight-bearing exercise, is included.

This point is well reflected in reactions on social media. On platforms like Reddit and Threads, articles reporting on "impact on bones" like this one often elicit three main types of responses. The first is, understandably, voices of anxiety and caution. Posts such as "I succeeded in losing weight, but was pointed out bone loss in a bone density test" or "I found bone loss in a DEXA scan in my 50s, and I'm concerned about the relationship with the medication" are actually seen. These voices are closer to the patient's real feelings, which cannot be fully captured in medical papers and should not be taken lightly.

The second type of response emphasizes background factors over "the drug itself". One post suggested, "It might not be tirzepatide itself but rather the effects of age or menopause. Calcium intake and strength training are also necessary." Women around menopause or post-menopause are already prone to bone loss. When weight loss and reduced food intake are added, it becomes difficult to attribute the cause solely to GLP-1 medications. While discussions on social media can be rough, they often reflect the reality that patients frequently face multiple factors simultaneously, which can be closer to the essence.

The third type of response is opposition to hasty conclusions. Many point out, "Osteoporosis is unlikely to develop in a short period," "Without pre-medication bone density data, causality cannot be determined," and "The general bone loss associated with rapid weight loss and the direct effects of GLP-1 medications should be considered separately." This is a very important perspective, highlighting the weaknesses of observational studies. There are many factors that affect bones, such as diet, supplement intake, exercise habits, menopausal status, medical history, and medication adherence. While there are emotional reactions on social media, there are also many voices cautious about "how to interpret the numbers."

In short, what's spreading on social media is not simple panic. There is both the emotion of "fear" and the rational question of "is it really just the drug's fault?" This is the current atmosphere surrounding GLP-1 medications. Once praised as a "dream weight loss drug," as more people use it and over longer periods, the discussion has shifted to more realistic side effect management. The current bone-related topic symbolizes this turning point.

However, it should not be forgotten that GLP-1 medications still offer significant benefits. Both in the Fox News article and related reports, experts uniformly emphasize, "Do not stop based on these results alone without consulting a doctor." Especially for those with high cardiovascular risk associated with diabetes or obesity, the benefits of GLP-1 medications often outweigh the concerns about bones. The issue is not whether there is zero risk, but rather how to optimize benefits and risks according to age and medical history.

So, what should be done in practice? A relatively reasonable approach at this point is for those using GLP-1 medications, especially the elderly, postmenopausal women, and those already at high risk for osteoporosis, to monitor not only weight loss but also bone and muscle indicators. Protein intake, calcium, vitamin D, strength training, walking, weight-bearing exercise, and bone density measurement if necessary. Some doctors may manage more closely, considering fall history, fracture history, duration of medication, and nutritional status. The important thing is not to assume "everything is going well because weight is dropping." Losing weight and becoming strong and healthy are not the same.

This study does not provide a decisive blow to overturn the evaluation of GLP-1 medications. However, it is not a small noise to be ignored either. The message that particularly careful observation is needed for the elderly and high-risk fracture groups is clear. As long-term follow-ups and prospective studies progress, it will become clearer whether it is a "direct effect of the drug," "secondary effects associated with rapid weight loss," or "apparent differences due to patient background."

The era of GLP-1 medications has already moved from questioning "whether they work" to questioning "how to continue using them safely." While focusing on the major benefits of weight loss, blood sugar improvement, and cardiovascular protection, we must not overlook the health of the foundation, including bones, muscles, and joints. What this report truly indicates is not fear of a trendy drug, but the simple yet often overlooked lesson that long-term use of medication requires a long-term perspective.

Source URL

1. Fox News (introducing a study indicating an 11% higher risk of fragility fractures in elderly type 2 diabetes patients after starting GLP-1 medications)
   https://www.foxnews.com/health/glp-1-drugs-tied-fracture-risk-older-adults-new-studies-suggest

2. Study published in the Journal of Clinical Endocrinology & Metabolism (primary study analyzing the association between GLP-1 receptor agonists and fragility fracture risk in type 2 diabetes patients aged 65 and older)
   https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgag056/8471581

3. PubMed page (used to confirm the abstract of the above JCEM study and verify the study's conclusions)
   https://pubmed.ncbi.nlm.nih.gov/41665888/

4. Health.com article (used to summarize another study presented at AAOS 2026 showing increased risks of osteoporosis, gout, and osteomalacia)
   https://www.health.com/glp-1s-may-increase-risk-of-osteoporosis-and-gout-11920266

5. AAOS 2026 Annual Meeting Press Kit (official summary of AAOS annual meeting presentation content, used to confirm 5-year risk figures and researcher comments)
   https://aaos-annualmeeting-presskit.org/2026/research-news/studies-explore-glp-1-receptor-agonist-use-and-its-impact-on-long-term-musculoskeletal-health/

6. AAOS conference abstract PDF (original abstract text of conference presentation on osteoporosis, gout, and osteomalacia)
   https://submissions.mirasmart.com/Verify/AAOS2026/Submission/out/AAOS2026-008736.PDF

7. PubMed published 2024 study (abstract of a randomized controlled trial showing different impacts on bone density with GLP-1 medication alone versus combined with exercise)
   https://pubmed.ncbi.nlm.nih.gov/38916894/

8. Reddit post: GLP-1’s and bone health (reference for perceptions on social media and forums about the importance of age, menopause, nutrition, and strength training)
   https://www.reddit.com/r/compoundedtirzepatide/comments/1otdlk9/glp1s_and_bone_health/

9. Reddit post: Zepbound/GLP-1 and bone density (reference for voices of concern from individuals worried about bone density loss on social media and forums)
   https://www.reddit.com/r/Zepbound/comments/1otdk9p/zepboundglp1_and_bone_density/

10. Reddit post: Osteoporosis (reference for cautious opinions on social media and forums suggesting the need to distinguish between general rapid weight loss and bone density loss)
    https://www.reddit.com/r/Mounjaro/comments/1ap3fsn/osteoporosis/

11. Reddit post: singer avery has osteoporosis “because of ozempic” (reference for the view on social media and forums that causality is difficult to determine without pre- and post-medication bone density data)
    https://www.reddit.com/r/Zepbound/comments/1iberl5/singer_avery_has_osteoporosis_because_of_ozempic/